2215-59-0 Usage
Physical appearance
Yellow crystalline solid This describes the color and form of the compound, which is important for its identification and handling.
Reactivity
Nitro group The presence of a nitro group in the compound makes it reactive, allowing it to participate in various chemical reactions.
Uses
Organic synthesis and pharmaceutical research 1-Benzyl-5-nitro-1H-indazol-3-ol is commonly used in these fields, making it an important compound for scientists and researchers.
Key precursor
Synthesis of pharmaceuticals and agrochemicals As a key precursor, the compound serves as a starting material for the production of various other chemicals, including medications and agricultural products.
Potential anti-tumor agent
Cancer research 1-Benzyl-5-nitro-1H-indazol-3-ol has shown promise in fighting cancer, making it a valuable compound in the search for new cancer treatments.
Versatility
Pharmaceutical and research industries The compound's various uses and properties make it an essential and adaptable resource in both the pharmaceutical and research sectors.
Check Digit Verification of cas no
The CAS Registry Mumber 2215-59-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,1 and 5 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2215-59:
(6*2)+(5*2)+(4*1)+(3*5)+(2*5)+(1*9)=60
60 % 10 = 0
So 2215-59-0 is a valid CAS Registry Number.
2215-59-0Relevant articles and documents
New cannabinoid receptor antagonists as pharmacological tool
Campillo, Nuria E.,Carrillo-López, Natalia,Girón, Rocío,González-Naranjo, Pedro,Martín-Fontelles, María I.,Martín-Vírgala, Julia,Naves, Manuel,Páez, Juan A.,Pérez, Concepción,Sánchez-Robles, Eva M.
, (2020/08/06)
Synthesis and pharmacological evaluation of a new series of cannabinoid receptor antagonists of indazole ether derivatives have been performed. Pharmacological evaluation includes radioligand binding assays with [3H]-CP55940 for CB1 and CB2 receptors and functional activity for cannabinoid receptors on isolated tissue. In addition, functional activity of the two synthetic cannabinoids antagonists 18 (PGN36) and 17 (PGN38) were carried out in the osteoblastic cell line MC3T3-E1 that is able to express CB2R upon osteogenic conditions. Both antagonists abolished the increase in collagen type I gene expression by the well-known inducer of bone activity, the HU308 agonist. The results of pharmacological tests have revealed that four of these derivatives behave as CB2R cannabinoid antagonists. In particular, the compounds 17 (PGN38) and 18 (PGN36) highlight as promising candidates as pharmacological tools.
